Reduced uptake of liposomal idarubicin in the perfused rat heart

Anti-Cancer Drugs

Volumn 19, Issue 7, 2008, Pages 729-732

  Sermsappasuk, Pakawadee ^a   Hrynyk, Rafal ^b   Gubernator, Jerzy ^c   Weiss, Michael ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^b CENTRAL INSTITUTE FOR LABOUR PROTECTION NATIONAL RESEARCH INSTITUTE   (Poland)

^c UNIVERSITY OF WROC AW   (Poland)

Author keywords

Cardiac uptake; Liposomal idarubicin; Perfused rat heart

Indexed keywords

CHOLESTEROL; IDARUBICIN; LIPOSOME; MACROGOL 2000; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLETHANOLAMINE; ANTINEOPLASTIC ANTIBIOTIC;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG UPTAKE; INOTROPISM; ISOLATED HEART; LIPOSOMAL DELIVERY; NANOENCAPSULATION; NONHUMAN; PRIORITY JOURNAL; ANIMAL; HEART MUSCLE; IN VITRO STUDY; METABOLISM; PERFUSION; RAT;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; IDARUBICIN; LIPOSOMES; MYOCARDIUM; PERFUSION; RATS;

EID: 51049117316     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e328304d948     Document Type: Article

References (15)

1. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 2004; 56:185-229.
2. Safra T. Cardiac safety of liposomal anthracyclines. Oncologist 2003; 8:17-24.
3. Theodoulou M, Hudis C. Cardiac profiles of liposomal anthracyclines: greater cardiac safety versus conventional doxorubicin? Cancer 2004; 100:2052-2063.
4. Hofheinz RD, Gnad-Vogt SU, Beyer U, Hochhaus A.Liposomal encapsulated anti-cancer drugs. Anti-Cancer Drugs 2005; 16:691-707.
5. Gabizon A, Dagan A, Goren D, Barenholz Y, Fuks Z. Liposomes as in vivo carriers of adriamycin: reduced cardiac uptake and preserved antitumor activity in mice. Cancer Res 1982; 42:4734-4739.
6. Oku N, Tokudome Y, Asai T, Tsukada H. Evaluation of drug targeting strategies and liposomal trafficking. Current Pharmaceutical Design 2000; 6:1669-1691.
7. Song H, Zhang J, Han Z, Zhang X, Li Z, Zhang L, et al. Pharmacokinetic and cytotoxic studies of pegylated liposomal daunorubicin. Cancer Chemother Pharmacol 2006; 57:591-598.
8. Weiss M, Kang W. P-glycoprotein inhibitors enhance saturable uptake of idarubicin in rat heart: pharmacokinetic/pharmacodynamic modeling. J Pharmacol Exp Ther 2002; 300:688-694.
9. Kang W, Weiss M. Kinetic analysis of saturable myocardial uptake of idarubicin in rat heart: effect of doxorubicin and hypothermia. Pharm Res 2003; 20:58-63.
10. Kang W, Weiss M. Caffeine enhances myocardial uptake of idarubicin but reverses its negative inotropic effect. Naunyn-Schmiedeberg's Arch Pharmacol 2003; 367:151-155.
11. Slifirski P, Szelejewski W, Grynkiewicz G, Gubernator J, Kozubek A. Liposomal formulation of idarubicin. Acta Pol Pharm 2003; 60:138-140.
12. Weiss M, Giessler C, Kang W. Effects of idarubicin and idarubicinol on rat coronary resistance and vasoconstrictor responsiveness of isolated aorta and mesentery. Anti-Cancer Drugs 2006; 17:69-74.
13. Kang W, Weiss M. Influence of P-glycoprotein modulators on cardiac uptake, metabolism and effects of idarubicin. Pharm Res 2001; 18: 1535-1541.
14. Hilmer SN, Cogger VC, Muller M, Le Couteur DG. The hepatic pharmacokinetics of doxorubicin and liposomal doxorubicin. Drug Metab Dispos 2004; 32:794-799.
15. Kang W, Weiss M. Modeling the metabolism of idarubicin to idarubicinol in rat heart: effect of rutin and phenobarbital. Drug Metab Disp 2003; 31: 462-468.